GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (XBRU:BCART) » Definitions » EV-to-Revenue

Biocartis Group NV (XBRU:BCART) EV-to-Revenue : 2.55 (As of May. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biocartis Group NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biocartis Group NV's enterprise value is €154.31 Mil. Biocartis Group NV's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €60.61 Mil. Therefore, Biocartis Group NV's EV-to-Revenue for today is 2.55.

The historical rank and industry rank for Biocartis Group NV's EV-to-Revenue or its related term are showing as below:

XBRU:BCART' s EV-to-Revenue Range Over the Past 10 Years
Min: 2   Med: 10.24   Max: 68.95
Current: 2.55

During the past 11 years, the highest EV-to-Revenue of Biocartis Group NV was 68.95. The lowest was 2.00. And the median was 10.24.

XBRU:BCART's EV-to-Revenue is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 3.195 vs XBRU:BCART: 2.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), Biocartis Group NV's stock price is €0.29. Biocartis Group NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.81. Therefore, Biocartis Group NV's PS Ratio for today is 0.36.


Biocartis Group NV EV-to-Revenue Historical Data

The historical data trend for Biocartis Group NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV EV-to-Revenue Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.39 8.32 6.86 6.42 2.55

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.42 - 2.55 -

Competitive Comparison of Biocartis Group NV's EV-to-Revenue

For the Diagnostics & Research subindustry, Biocartis Group NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's EV-to-Revenue falls into.



Biocartis Group NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biocartis Group NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=154.305/60.612
=2.55

Biocartis Group NV's current Enterprise Value is €154.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €60.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV  (XBRU:BCART) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biocartis Group NV's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.29/0.806
=0.36

Biocartis Group NV's share price for today is €0.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was €0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocartis Group NV (XBRU:BCART) Business Description

Traded in Other Exchanges
N/A
Address
Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV (XBRU:BCART) Headlines

No Headlines